2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.
The traditional holiday season is upon us, in the most untraditional of times. While December usually offers “best of” articles or a round-up of the year, this year is more about looking forward to 2021 and what that will bring. And we are lucky to have science on our side, with the vaccines rounding the corner. Nowhere in recent memory has the biopharma industry been more a part of the daily conversation than the past nine months. And behind the scenes, companies quickly pivoted, collaborated, partnered, and shifted gears to address COVID-19 itself, or keep its business running on the therapeutic interest at hand. We will see more next year what COVID has meant to prescriptions, diagnoses, clinical trials or changes in commercialization, and we will be right there detailing that in the coming months, as we have during the past year.
Our January magazine is our milestone Industry Outlook issue, which features the near-term trends contributed to us by our esteemed Editorial Advisory Board. We usually have such a long list, that we choose a final 8-10 on which to focus. But the outlying trends still weigh in on the overall industry, so let’s take a look at what we won’t be taking a deeper dive on.
Lisa Henderson, Editor-in-Chief
Then there are other trends that were discussed and will be fleshed out in much more detail in the coming months. Those include sales force structure changes in regard to HCP engagement/environment; diversity in clinical trials; IP sharing and pre-competitive collaborations; pharma’s interaction with PBMs and payers; and our regularly scheduled appearances of the HBA Woman of the Year, Emerging Pharma Leaders, our Pharma 50, and more.
This time last year, we surely didn’t know what was coming our way. But watching the industry respond and pivot and bring its best to bear on multiple levels has been an inspiration.
All of us at Pharmaceutical Executive wish you a safe and happy new year.
Lisa Henderson is Pharm Exec’s Editor-in-Chief. She can be reached at lhenderson@mjhlifesciences.com.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
FDA Grants Priority Review to AstraZeneca’s Calquence for Previously Untreated Mantle Cell Lymphoma
October 3rd 2024Priority Review was based on data from the ECHO Phase III trial, which demonstrated that a combination of Calquence, bendamustine, and rituximab reduced the risk of disease progression or death by 27% in patients with previously untreated mantle cell lymphoma.
FDA Approves Fresenius Kabi, Formycon’s Stelara Biosimilar for Multiple Inflammatory Diseases
October 2nd 2024Marketed as a biosimilar to Stelara, approval of Otulfi was based on clinical data demonstrating comparable efficacy in treating inflammatory conditions such as Crohn disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis.